isoxazoles has been researched along with Yellow Fever in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhowmick, B; Chen, J; Han, Q; Hang, J; Liao, C; Upadhyay, A; Wang, H; Wang, Q; Wu, S; Zhang, Y | 1 |
| Martins-Filho, OA; Mota, LM; Oliveira, AC; Santos-Neto, LL; Simões, M; Tauil, PL | 1 |
2 other study(ies) available for isoxazoles and Yellow Fever
| Article | Year |
|---|---|
Functional analysis reveals ionotropic GABA receptor subunit RDL is a target site of ivermectin and fluralaner in the yellow fever mosquito, Aedes aegypti.
Topics: Aedes; Animals; Female; Insecticides; Isoxazoles; Ivermectin; Larva; Receptors, GABA; Yellow Fever | 2022 |
Seroconversion in patients with rheumatic diseases treated with immunomodulators or immunosuppressants, who were inadvertently revaccinated against yellow fever.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheumatoid; Brazil; Child; Contraindications; Female; Humans; Immunity, Innate; Immunization, Secondary; Immunologic Factors; Immunosuppressive Agents; Infliximab; Isoxazoles; Leflunomide; Lupus Erythematosus, Systemic; Middle Aged; Retrospective Studies; Rheumatic Diseases; Rituximab; Scleroderma, Systemic; Yellow Fever; Yellow Fever Vaccine; Young Adult | 2015 |